Outcomes for the third key question were safety outcome measures mainly referred to adverse events occurring with treatment, including constipation, nausea, vomiting, diarrhea, decreased appetite, hypoglycaemia, and severe side-effects
This may be attributed to muscle strength loss and reduction in physical efficiency along with the accompanied risk of developing insulin resistance if lean mass is diminished [164]
According to a recent ET Pharma report, the expiration of semaglutides patent across India, emerging economies, and select regulated markets like Canada and Brazil could unlock a revenue pool exceeding Rs
Combining it with Insulin or Sulfonylureas may increase the risk of low blood sugar
It's worth noting that pancreatitis and gallbladder disease are recognised risks that can present with abdominal pain radiating to the back